John N. Allan, MD | Authors

John N. Allan, MD, on the Impact of First-Line Ibrutinib in Patients with CLL, TP53 Aberrations

December 07, 2020

This pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.

John N. Allan, MD, on Research Coming Out of ASH for CLL

December 05, 2020

The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill Cornell Medicine spoke about exciting research coming out of ASH for patients with chronic lymphocytic leukemia.